Experiments performed in bone-conditioned media suggest that in addition to enhancing viability, locally produced estrogen also sustains ER+ breast cancer cell proliferation, and that aromatase inhibitors directly modulate this axis. This evidence concerns the gene CYP19A1 and breast carcinoma.